Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib-Reference-Cited by-同舟云学术

Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib

Published:2013-10 Issue:5 Volume:13 Page:584-591
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Cortes Jorge E.,Nicolini Franck E.,Wetzler Meir,Lipton Jeffrey H.,Akard Luke,Craig Adam,Nanda Nisha,Benichou Annie-Claude,Leonoudakis Janis,Khoury H. Jean,Hochhaus Andreas,Baccarani Michele,Kantarjian Hagop M.

Funder

ChemGenex Pharmaceuticals

Teva Pharmaceutical Industries Ltd.

MD Anderson Cancer Center

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference35 articles.

1. Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study

2. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis;de Lavallade;J Clin Oncol,2008

3. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med,2006